【摘要】：正世界范圍內(nèi),宮頸癌是女性發(fā)病率和死亡率最高的第4類惡性腫瘤,僅次于乳腺癌、結(jié)直腸癌和肺癌。每年大約有527 600例新發(fā)病例,265 000例死亡病例。在不發(fā)達(dá)國(guó)家,是女性第2位常見(jiàn)惡性腫瘤和第3位致死性惡性腫瘤。超過(guò)85%的新診斷病例發(fā)生在經(jīng)濟(jì)不發(fā)達(dá)人群,幾乎90%的宮頸癌死亡發(fā)生于經(jīng)濟(jì)不發(fā)達(dá)地區(qū)。1分期和臨床評(píng)估注意事項(xiàng)宮頸癌FIGO分期為臨床分期。最新的FIGO
[Abstract]:Worldwide, cervical cancer is the fourth highest morbidity and mortality in women, second only to breast cancer, colorectal cancer and lung cancer. Each year there are about 527,600 new cases and 265,000 deaths. In underdeveloped countries, it is the second most common malignant tumor in women and the third fatal malignant tumor. More than 85% of the newly diagnosed cases occurred in economically underdeveloped population, and almost 90% of cervical cancer deaths occurred in economically underdeveloped areas. The latest FIGO
【作者單位】： 中山大學(xué)孫逸仙紀(jì)念醫(yī)院婦產(chǎn)科;
【分類號(hào)】：R737.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 高燕華;宮頸癌局部穿刺化療操作的配合與護(hù)理觀察[J];解放軍護(hù)理雜志;2005年04期

2 耿京;唐軍;趙e，

本文編號(hào)：2364680